Artist’s Illustration of DeltaRex-G that hunts down tumors and nowhere else and kills cancer cells, cancer stem cells and their blood supply.
Enhanced Enhanced CCNG1 expression in tumors of patients with osteosarcoma and soft tissue sarcomas: A novel biomarker for DeltaRex-G CCNG1 inhibitor therapy
Our mission is to expedite the development of gene targeted technologies for cancer and Parkinson’s disease.
PRESENTED BY DR. SANT P. CHAWLA AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY
โ Sant P. Chawla, MD
LOS ANGELES, CALIFORNIA, UNITED STATES OF AMERICA, October 24, 2023 /EINPresswire.com/ — The Aveni Foundation and the Sarcoma Oncology Research Center, Santa Monica CA, are proud to announce the results of a research collaboration with BostonGene Corp., Waltham MA, wherein AI analysis showed enhanced CCNG1 oncogene expression in all tumors of patients with osteosarcoma, chondrosarcoma, leiomyosarcoma and other soft tissue sarcomas tested so far (ANN ONCOL VOLUME 34, SUPPLEMENT 2, S1056-S1057, OCTOBER 2023. DOI:https://doi.org/10.1016/j.annonc.2023.09.1209). Currently, a number of patients whose tumors show high, medium high and medium low CCNG1 expression are currently receiving DeltaRex-G as platform therapy upon which other FDA approved cancer drugs/immunotherapies have been added. This regulatory authorization by the United States Food and Drug Administration/Center for Biologics Evaluation Research is based on CCNG1 enhanced expression in all tumors tested and on Phase 1/2 studies demonstrating safety and efficacy of DeltaRex-G for advanced pancreatic cancer, sarcoma, and breast cancer, and long term (>10-year) survival data with DeltaRex-G gene therapy. Prospective Phase 2 studies are planned to evaluate the safety and efficacy of DeltaRex-G combination regimens, and to correlate tumor response with CCNG1 expression level in sarcoma tumors (Chawla et al., presented at the European Society of Medical Oncology Annual Meetings, October 20-24,2023).
DeltaRex-G is a targeted gene therapy vector that seeks out the biochemical signatures (SIG) of all invading cancers. Taken off the shelf and injected intravenously, DeltaRex-G effectively tracks down and binds to SIG proteins in the tumor microenvironment and kills rapidly dividing cancer cells, tumor associated fibroblasts and tumor associated microvasculature, without causing the side effects of chemotherapy and ungoverned immunotherapy agents. And since DeltaRex-G reduces stroma production as well as kills cancer cells, DeltaRex-G enhances immune cell trafficking in the tumor microenvironment, therefore serving as an immune modulator, according to Dr. Chawla.
For further information, please go to the following websites: www.avenifoundation.org, www.sarcomaoncology.com or contact Dr. Gordon at [email protected] or [email protected]. To make a donation, please visit our website at www.avenifoundation.org and click on the โdonateโ button for credit card donations.
Erlinda Maria Gordon
Aveni Foundation
+1 310-552-9999
email us here
Originally published at https://www.einpresswire.com/article/663730271/ai-analysis-shows-enhanced-ccng1-expression-in-sarcoma-a-novel-biomarker-for-deltarex-g-ccng1-inhibitor-therapy
